5 edition of Positron emission tomography and autoradiography found in the catalog.
Includes bibliographies and index.
|The Physical Object|
|Pagination||xvi, 62 p. :|
|Number of Pages||74|
nodata File Size: 8MB.
The book contains 12 high-quality color illustrations culled from nine tomography centers across Europe and North America. No obvious damage to the cover, with the dust jacket if applicable included for hard covers. This book contains the following five chapters: Positron Emission Tomography PET in Psychiatry; Regional Cerebral Blood Flow CBF in Psychiatry: Methodological Issues; Regional Cerebral Blood Flow in Psychiatry: Application to Clinical Research; Regional Cerebral Blood Flow in Psychiatry: The Resting and Activated Brains of Schizophrenic Patients; and Brain Electrical Activity Mapping BEAM in Psychiatry.
Some of the titles are: Positron Emission Tomography Instrumentation, Generator Systems for Positron Emitters, Reconstruction Algorithms, Cerebral Glucose Consumption: Methodology and Validation, Cerebral Blood Flow Tomography Using Xenon-133 Inhalation: Methods and Clinical Applications, PET Studies of Stroke, Cardiac Positron Emission Tomography, and Use of PET in Oncology.
To assess reproducibility, four patients were studied on two occasions 1 month apart. This preliminary work demonstrates the local quantification of these important functional parameters, and indicates the potential usefulness of studying their pathophysiological interrelationship in brain disease. The use of these different methods in the validation of tracers and for supplying complementary information is illustrated.
This a text on cerebral and myocardial imaging using positron emission tomography and autoradiography. The method is easy to learn and set up, and should be included in all PET research and development labs. When tracer administration is not Positron emission tomography and autoradiography by mass due to specific radioactivity, 11C-tracers can also be readily used.
Conclusion: PET imaging using 68Ga-Fucoidan represents a valuable tool for assessing p-selectin activation in vivo discriminating ischemic stroke early after stroke onset. Keywords: 68Ga-Fucoidan; Cerebral ischemia; PET imaging; molecular biomarker; p-selectin; photothrombosis. 38 at 48 h after stroke, compared to 1. Control animals and those scanned at 24-26 h and 48 h after stroke exhibited no elevated 68Ga-Fucoidan uptake in either hemisphere.
The authors discuss that PET is being used principally in research and that its future, although theoretically unlimited, depends on the development of ''further labeled compounds. Complete electrocardiographic and tomographic concordance was observed for the locus of all transmural infarcts.
It must, however, be realized that a large fraction of these candidates will fail to characterize the desired biochemistry in vivo due to undesirable properties that are not relevant to providing a specific signal in vitro.
May be very minimal identifying marks on the inside cover. It must, however, be realized that a large fraction of these candidates will fail to characterize the desired biochemistry in vivo due to undesirable properties that are not relevant to providing a specific signal in vitro. The method is easy to learn and set up, and should be included in all PET research and development labs.
Here, we evaluated the specific p-selectin inhibitor fucoidan labeled with gallium-68 68Ga-Fucoidan as an imaging biomarker for assessing p-selectin activation in acute ischemic stroke using Positron Emission Tomography PET.